RxDoctor Payments Data

German Lasala, MD

Internal Medicine · Tucson, AZNPI 1124086392

Payments from drug & device makers

$1,111in general payments, 2019–2025

Across 16 payments — averaging $69.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$133
  • AstraZeneca$131
  • Amarin Pharma, Inc.$125
  • Idorsia Pharmaceuticals US Inc$122
  • Stryker$122
  • Novo Nordisk$118
  • plus $361 from 8 others

What the payments were for

  • Food & beverage$1,10599%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,111 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$168,497
Medicare patients
243
Services billed
14,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide116$183,866
EliquisApixaban48$71,452
OzempicSemaglutide45$67,921
CreonLipase/Protease/Amylase16$37,423
FarxigaDapagliflozin Propanediol36$29,216
Repatha SureclickEvolocumab36$28,510
LinzessLinaclotide15$22,089
XareltoRivaroxaban15$18,647
RybelsusSemaglutide13$18,422
Tresiba Flextouch U-200Insulin Degludec25$17,612
GemtesaVibegron25$16,807
JardianceEmpagliflozin13$15,616
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,528
Xtampza ErOxycodone Myristate13$12,444
Dexlansoprazole DrDexlansoprazole17$7,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$75$183,866116 claims
Novo NordiskOzempic, Rybelsus$118$86,34358 claims
AstraZenecaFarxiga$131$29,21636 claims
GSKTrelegy Ellipta, Anoro Ellipta$109$18,32131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →